

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

NCT06873516

Status	RECRUITING
Phase	Phase 2
Sponsor	Evommune, Inc.
Enrollment	160 participants

Key Eligibility Criteria

Inclusion (3)

- Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
- Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
- Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.

Exclusion (4)

- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
- Use of certain medications.
- History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
- Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.

Locations (53 total)

Cahaba Dermatology Skin Health Center, Birmingham, Alabama, United States
Velocity Clinical Research, Mobile, Mobile, Alabama, United States
Center for Dermatology Clinical Research, Fremont, California, United States
... and 50 more locations